EDUCATION

Internship

Pediatrics
  • Boston Children's Hospital , 1994 , Boston , MA

Medical School

  • University of Massachusetts , 1993 , Worcester , MA

Residency

Pediatrics
  • Boston Combined Residency Program (BCRP) , 1996 , Boston , MA

Undergraduate Degree

  • University of Pennsylvania , 1989 , Philadelphia , PA

Fellowship

Pediatric Hematology -Oncology
  • Children's Hospital of Philadelphia , 2000 , Philadelphia , PA

CERTIFICATIONS

  • American Board of Pediatrics, Pediatric Hematology and Oncology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Mar 09. View abstract
  2. Facial Paralysis From Post-Transplant Lymphoproliferative Disorder. Otol Neurotol. 2021 Jan 13. View abstract
  3. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View abstract
  4. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. View abstract
  5. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View abstract
  6. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. View abstract
  7. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 10 15; 25(20):6044-6051. View abstract
  8. Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11). View abstract
  9. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View abstract
  10. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View abstract
  11. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. View abstract
  12. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct; 61(10):1792-7. View abstract
  13. Neuroblastoma presenting as facial nerve palsy and bulging tympanic membrane. Clin Pediatr (Phila). 2015 Feb; 54(2):183-5. View abstract
  14. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. View abstract
  15. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med. 2013 Aug; 38(8):604-7. View abstract
  16. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res. 2012 12 15; 18(24):6732-41. View abstract
  17. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7. View abstract
  18. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. Semin Nucl Med. 2011 Sep; 41(5):354-63. View abstract
  19. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22. View abstract
  20. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65. View abstract
  21. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011 Mar 01; 29(7):839-44. View abstract
  22. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 01; 70(23):9554-61. View abstract
  23. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. View abstract
  24. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 01; 27(7):1020-5. View abstract
  25. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006 Jun 15; 66(12):6050-62. View abstract
  26. 131I-Metaiodobenzylguanidine(131I-MIBG) double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2006; 123. View abstract
  27. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2006. View abstract
  28. Expression profiling identifies BAI2, an endogenous inhibitor of angiogenesis, as a traget for somatic inactivation in high-risk neuroblastoma. Advances in Neuroblastoma Research Proceedings. 2006; 73. View abstract
  29. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005 Oct 18; 228(1-2):171-9. View abstract
  30. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res. 2005 Apr 01; 11(7):2680-5. View abstract
  31. Somatic Inactivation of brain-specific angiogenesis inhibitor-2 (BAI2) during the malignant evolution of high-risk neuroblastoma. Pediatric Blood and Cancer. 2005; 44(6). View abstract
  32. Genome-wide transcriptome analysis for neuroblastoma gene discovery and refinement of clinical risk group prediction. Advances in Neuroblastoma Research Proceedings. 2004; 103. View abstract
  33. 131I-MIBG double infusiton with autologous stem cell transplant (ASCT) for neuroblastoma - a New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2004; 65. View abstract
  34. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol. 2003 Dec; 16(12):1248-56. View abstract
  35. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15; 63(22):7861-9. View abstract
  36. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res. 2003 Apr 01; 63(7):1631-5. View abstract
  37. Functional genomic analysis of neuroblastoma for high resolution mapping of 11q deletions. American Association for Cancer Research Proceedings. 2003; 44:1394. View abstract
  38. Transplantation in Hematology and Oncology II. 2003; 283-98. View abstract
  39. Discovery of antiangiogenic targets induced by chemotherapy in a murine model of human neuroblastoma. American Association for Cancer Research Proceedings Late Breaking Abstracts. 2003. View abstract
  40. Transfusion of the patient with congenitally aquired coagulation defects. Hillyer CD and Silbersteing LE, editors. Principles of Blood Banking and Transfusion Medicine. 2003; 291-306. View abstract
  41. Increased incidence of TP53 mutations in post-treatment neuroblastomas. American Association for Cancer Research Proceedings. 2003; 44:809. View abstract
  42. A reversible methionine aminopeptidase inhibitor potently inhibits growth of human neuroblastoma in xenotransplantation models. American Association fo Cancer Research Proceedings. 2003; 44:809. View abstract
  43. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2003; 2263-76. View abstract
  44. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 2002 Nov 15; 62(22):6651-8. View abstract
  45. Chromosome 11q23.3-q24.1 deletions in neuroblastoma (NB). Advances in Neuroblastoma Research Proceedings. 2002; 18. View abstract
  46. ID2 is a MYCN target gene, but expression is not correlated with MYCN gene amplification in human neuroblastomas. Advances in Neuroblastoma Research Proceedings. 2002; 50. View abstract
  47. A functional and expression profiling stratefy for isolating neuroblastoma (NB) supressor genes on chromosome 11. Advances in Neuroblastoma Research Proceedings. 2002; 18. View abstract
  48. Prospective validation of real-time quantitative PCR for detection of MYCN amplifcation inprimary neuroblastoma specimens. Advances in Neuroblastoma Research Proceedings. 2002; 67. View abstract
  49. A combined functional and expression profiling strategy for isolating neuroblastoma suppresso genes on chromosome 11. American Association for Cancer Research Proceedings. 2002; 43:343. View abstract
  50. Angiogenesis inhibition is an effective adjuvant therapeutic strategy in neuroblastoma (NB) preclinical models. Advances in Neuroblastoma Research Proceeddings. 2002; 87. View abstract
  51. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res. 2001 Apr; 7(4):977-84. View abstract
  52. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res. 2001 Apr; 7(4):1026-32. View abstract
  53. The growth rate of human neuroblastoma xenografts is decreased through inhibition of multiple angiogenic signaling pathways with SU668. Journal of Pediatric Hematology/Oncology . 2001; 23:A1. View abstract
  54. Inhibition of the VEGF, PDGF and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts. American Association for Cancer Research Proceedings. 2001; 42:803. View abstract
  55. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth especially in the setting of subclinical disease. Clinical Cancer Research. 2001; 7(4):977-84. View abstract
  56. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol. 2000 Dec; 35(6):673-6. View abstract
  57. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol. 2000 Dec; 35(6):526-30. View abstract
  58. Long term survivors of childhood leukemia. Curr Opin Hematol. 2000 Jul; 7(4):217-22. View abstract
  59. Detection of unbalanced 17q gain in human neuroblastomas by real-time quantitative PCR. American Association for Cancer Research Proceedings. 2000; 41:791. View abstract
  60. Use of real-time quantitative PCR to detect unbalanced 17q gain in neuroblastoma cell lines and primary tumors. Medical and Pediatric Oncology. 2000; 35:748. View abstract
  61. Microcytic Anemia. Iron Deficiency Anemia. The 5 Minute Pediatric Consult. 2000. View abstract
  62. Effects of TRK receptor expression on angiogenesis in neuroblastoma cells. American Association for Cancer Research Proceedings. 2000; 41:791. View abstract
  63. Inhibitors of angiogenesis in minimal residual disease: safety post-BMT and efficacy in a preclinical model. Angiogenesis in Oncology and Hematology. 2000. View abstract
  64. Preclinical evaluation of antiangiogenic therapy with TNP-470 for human neuroblastoma. Molecular Targets and Cancer Therapeutics. 1999; 5:3812s. View abstract
  65. TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts. Journal of Pediatric Hematology/Oncology. 1999; 21:326. View abstract
  66. A 2.5-month-old girl with hyperbilirubinemia, hypoglycemia, and blindness. Curr Opin Pediatr. 1996 Aug; 8(4):411-6. View abstract